| 000 | 01899 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250513121409.0 | ||
| 264 | 0 | _c19970710 | |
| 008 | 199707s 0 0 eng d | ||
| 022 | _a0732-183X | ||
| 024 | 7 |
_a10.1200/JCO.1997.15.4.1470 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDawson, N A | |
| 245 | 0 | 0 |
_aPhase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer. _h[electronic resource] |
| 260 |
_bJournal of clinical oncology : official journal of the American Society of Clinical Oncology _cApr 1997 |
||
| 300 |
_a1470-7 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Hormonal _xadministration & dosage |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 |
_aFlutamide _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLeuprolide _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aProstate-Specific Antigen _xblood |
| 650 | 0 | 4 |
_aProstatic Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aSuramin _xadministration & dosage |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aFigg, W D | |
| 700 | 1 | _aCooper, M R | |
| 700 | 1 | _aSartor, O | |
| 700 | 1 | _aBergan, R C | |
| 700 | 1 | _aSenderowicz, A M | |
| 700 | 1 | _aSteinberg, S M | |
| 700 | 1 | _aTompkins, A | |
| 700 | 1 | _aWeinberger, B | |
| 700 | 1 | _aSausville, E A | |
| 700 | 1 | _aReed, E | |
| 700 | 1 | _aMyers, C E | |
| 773 | 0 |
_tJournal of clinical oncology : official journal of the American Society of Clinical Oncology _gvol. 15 _gno. 4 _gp. 1470-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1200/JCO.1997.15.4.1470 _zAvailable from publisher's website |
| 999 |
_c9173925 _d9173925 |
||